CARIBOU BIOSCIENCES INC

CRBU is the Nasdaq ticker symbol for Caribou Biosciences, Inc., a clinical-stage biotechnology company. The stock represents equity ownership in the company and trades on the Nasdaq Global Select Market. Like other biotech stocks, CRBU's value is closely tied to its pipeline progress, clinical trial results, and regulatory developments rather than current commercial sales.

CRBU's recent performance is displayed on this page, including current price, daily change, and longer-term trends. As a clinical-stage biotech, the stock can be sensitive to trial data, financing news, and sector sentiment. For the latest price and percentage moves, refer to the live quote and performance data shown above.

CRBU's price moves with investor expectations about its clinical programs, cash runway, and competitive position. News such as trial results, regulatory filings, partnership announcements, and equity offerings can shift sentiment. Broader market conditions, interest rates, and biotech sector rotation also influence the stock, often making it more volatile than large-cap peers.

CRBU shares can be bought through a brokerage account that offers Nasdaq-listed stocks. You can place a market or limit order during regular trading hours, typically 9:30 a.m. to 4:00 p.m. ET. Some brokers also allow extended-hours trading. Fractional shares may be available depending on the broker. Check commissions and order types before trading.

Key risks include clinical trial failure, regulatory delays, and the need for additional capital, which can dilute existing shareholders. As a clinical-stage company, CRBU may have no approved products or product revenue. Competition, manufacturing challenges, and reliance on key personnel also pose risks. Market sentiment toward biotech can amplify price swings.

For a clinical-stage biotech like CRBU, relevant metrics include cash and cash equivalents, quarterly cash burn, and projected runway. Research and development expenses, general and administrative costs, and shares outstanding help assess dilution risk. Revenue may be minimal or absent, so investors often focus on pipeline milestones, trial timelines, and partnership terms rather than traditional earnings multiples.